## MAINE STATE LEGISLATURE

The following document is provided by the

LAW AND LEGISLATIVE DIGITAL LIBRARY

at the Maine State Law and Legislative Reference Library

http://legislature.maine.gov/lawlib



Reproduced from scanned originals with text recognition applied (searchable text may contain some errors and/or omissions)



## 119th MAINE LEGISLATURE

## **FIRST REGULAR SESSION-1999**

Legislative Document

No. 2082

S.P. 732

In Senate, March 30, 1999

An Act to Reduce the Cost of Prescription Drugs to Residents of the State.

Reference to the Committee on Health and Human Services suggested and ordered printed.

JOY J. O'BRIEN Secretary of the Senate

Presented by Senator PARADIS of Aroostook. (GOVERNOR'S BILL). Cosponsored by Representative LOVETT of Scarborough and Senators: BENOIT of Franklin, BERUBE of Androscoggin, Representatives: BRAGDON of Bangor, FULLER of Manchester, KANE of Saco, KNEELAND of Easton, QUINT of Portland, TWOMEY of Biddeford.

	Be it enacted by the People of the State of Maine as follows:
2	Sec. 1. 22 MRSA §254-B is enacted to read:
<b>4</b> 6	§254-B. Maine resident low-cost prescription drug program
8	The department shall conduct a program to provide low-cost prescription drugs to residents of this State.
10	1. Agreement. A drug manufacturer who sells prescription drugs in this State may enter into a rebate agreement with the
12	department; the agreement must be modeled after Section 1927 of the United States Social Security Act and include the requirement
14	that the manufacturer make rebate payments to the State each calendar quarter or according to a schedule established by the
16	department.
18	2. Rebate amount. The rebate amount required from a manufacturer to the State is equivalent to the rebate amount
20	calculated under the Medicaid Rebate Program pursuant to 42 United States Code, Section 1396r-8.
22	3. Discount to residents of the State. Any retail pharmacy
24	in the State that sells drugs covered by an agreement pursuant to subsection 1 shall discount the retail price of those drugs sold
26	to residents of the State by the rebate amount pursuant to subsection 2, less the administrative costs of the program
28	pursuant to subsection 6.
30	4. Operation of program. Retail pharmacies in the State shall submit claims to the department to verify the amount of
32	discount due the resident. The pharmacies shall charge residents of the State the current retail price charged by each pharmacy
34	for that prescription drug to persons purchasing that drug who are not covered by insurance or 3rd-party payor plans, less the
36	discount amount, pursuant to subsection 3.
38	The amount of the discount must be indicated on the resident's receipt. On a weekly or biweekly basis, the pharmacy must be
40	reimbursed by the department for drug discounts provided to residents of the State. The department shall collect the
42	necessary utilization data from the pharmacies submitting claims in order to comply with 42 United States Code, Section 1396r-8.
44	5. Discrepancies in rebate amounts. Discrepancies in
46	rebate amounts must be resolved using the process established in

48

50

this subsection.

A. If there is a discrepancy in the manufacturer's favor between the amount claimed by a pharmacy or other business licensed to dispense prescription drugs in this State and

the amount rebated by the manufacturer, the department, at
the department's expense, may hire a mutually agreed-upon independent auditor. Following the audit, if a discrepancy still exists, the manufacturer shall justify the reason for the discrepancy or make payment to the department for any additional amount due.

B. If there is a discrepancy against the interest of the manufacturer in the information provided by the department to the manufacturer pursuant to subsection 3, paragraph A, the manufacturer, at the manufacturer's expense, may hire a mutually agreed-upon independent auditor to verify the accuracy of the data supplied to the department. Following the audit, if a discrepancy still exists, the department shall justify the reason for the discrepancy or refund to the manufacturer any excess payment made by the manufacturer.

C. Following the procedures established in paragraph A or B, either the department or the manufacturer may request a hearing before the Administrative Hearings Unit. Supporting documentation must accompany the request for a hearing.

6. Administrative costs for program. Administrative costs for the program must be funded solely from the rebates received from the pharmaceutical manufacturers. The department may not spend more for the administrative costs of this program than it spends on the elderly low-cost drug program.

- 7. Obligation of retail pharmacies in State. The obligation of retail pharmacies in the State to discount drugs to residents of the State does not begin until 3 months after the drug manufacturer begins to pay the rebate to the department.
- 8. Annual summary report. The department shall report the status of the program to the Legislature on an annual basis.

## 38 SUMMARY

This bill establishes a program to provide low-cost prescription drugs to Maine residents by giving prescription drug manufacturers the option of entering into a voluntary drug rebate agreement. The program is modeled after the rebate agreement used in the State's Medicaid and elderly low-cost drug programs. The rebate amount must be applied to the cost of the prescription drugs purchased by residents of the State.